A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Inclusion Criteria:
Exclusion Criteria:
Has SBP ≥170 mmHg and/or DBP ≥110 mmHg at Visit 1 or at Visit 3.
Has known secondary causes of hypertension
Have heart failure with reduced ejection fraction (HFrEF) diagnosis
Have had any of the following conditions within 90 days prior to screening.
Have type 1 diabetes (T1D)
Have acute or chronic hepatitis, including a history of autoimmune hepatitis
Troy, Michigan 48098, United States
North Richland Hills, Texas 76180, United States
Rosario, 2000, Argentina
Chongqing, 400010, China
Luoyang Shi, 471003, China
Pardubice V, 530 02, Czechia
Dresden, 01277, Germany
Kamakura-shi, 247-0056, Japan
Yamato-shi, 242-0004, Japan